Achieve Life Sciences (NASDAQ:ACHV) Shares Cross Above 200-Day Moving Average of $2.80

Achieve Life Sciences Inc (NASDAQ:ACHV) shares passed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $2.80 and traded as high as $2.20. Achieve Life Sciences shares last traded at $2.19, with a volume of 2,600 shares changing hands.

A number of research analysts have weighed in on the stock. Maxim Group set a $6.00 price target on shares of Achieve Life Sciences and gave the company a “buy” rating in a research note on Friday, August 9th. ValuEngine raised shares of Achieve Life Sciences from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Finally, LADENBURG THALM/SH SH reissued a “buy” rating and issued a $20.00 price objective on shares of Achieve Life Sciences in a research report on Friday, August 9th.

The stock’s 50-day moving average price is $1.93 and its 200 day moving average price is $2.80. The company has a debt-to-equity ratio of 0.02, a current ratio of 3.62 and a quick ratio of 3.62. The firm has a market cap of $19.60 million, a P/E ratio of -0.63 and a beta of 1.96.

Achieve Life Sciences (NASDAQ:ACHV) last announced its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.50) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.33) by ($0.17). As a group, analysts forecast that Achieve Life Sciences Inc will post -1.6 EPS for the current fiscal year.

Several hedge funds have recently made changes to their positions in ACHV. Searle & CO. raised its position in Achieve Life Sciences by 80.4% during the second quarter. Searle & CO. now owns 132,592 shares of the biopharmaceutical company’s stock worth $256,000 after acquiring an additional 59,092 shares in the last quarter. Renaissance Technologies LLC raised its position in Achieve Life Sciences by 12.5% during the second quarter. Renaissance Technologies LLC now owns 321,268 shares of the biopharmaceutical company’s stock worth $620,000 after acquiring an additional 35,607 shares in the last quarter. Vanguard Group Inc. raised its position in Achieve Life Sciences by 152.2% during the second quarter. Vanguard Group Inc. now owns 274,519 shares of the biopharmaceutical company’s stock worth $530,000 after acquiring an additional 165,667 shares in the last quarter. Sio Capital Management LLC raised its position in Achieve Life Sciences by 24.4% during the second quarter. Sio Capital Management LLC now owns 524,413 shares of the biopharmaceutical company’s stock worth $1,012,000 after acquiring an additional 102,934 shares in the last quarter. Finally, Jane Street Group LLC bought a new stake in Achieve Life Sciences during the second quarter worth $32,000. 18.63% of the stock is currently owned by institutional investors and hedge funds.

Achieve Life Sciences Company Profile (NASDAQ:ACHV)

Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes smoking cessation aids in the United States and internationally. The company offers Cytisine, a plant-based alkaloid that interacts with nicotine receptors in the brain to help reduce the severity of nicotine withdrawal symptoms.

Read More: Analyst Ratings Trading

Receive News & Ratings for Achieve Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achieve Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.